Buck, Andreas K. 1970-
Andreas K. Buck researcher
VIAF ID: 47599245 ( Personal )
Permalink: http://viaf.org/viaf/47599245
Preferred Forms
- 100 0 _ ‡a Andreas K. Buck ‡c researcher
- 100 1 _ ‡a Buck, Andreas K. ‡d 1970-
4xx's: Alternate Name Forms (5)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [\(^I&T during long-term follow-up | |
CXCR4-targeted theranostics in oncology | |
Development of discordant hypermetabolic prostate cancer lesions in the course of [177Lu]PSMA radioligand therapy and their possible influence on patient outcome | |
Expression von EGF-R, c-erb B2, TGF-alpha und p53 in der Frühphase der Karzinogenese im BOP-induzierten Pankreaskarzinom des Syrischen Goldhamsters mit vergleichender Darstellung im simultan entstandenen primären Leberkarzinom | |
Lenvatinib | |
Lenvatinib Multikinaseinhibitoren - die erste effektive Therapie für das Radiobiod-refraktäre differenzierte Schilddrüsenkarzinom | |
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease | |
Molekulare Bildgebung der Proliferation in vivo mit Positronen-Emissions-Tomographie | |
Predictive value of 18 F-FDG PET in patients with advanced medullary thyroid carcinoma treated with vandetanib | |
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy | |
Questions and controversies in the clinical application of tyrosine kinase inhibitors to treat patients with radioiodine-refractory differentiated thyroid carcinoma: expert perspectives | |
Reduced segmentation of lesions is comparable to whole-body segmentation for response assessment by PSMA PET/CT: initial experience with the keyhole approach | |
Repair of a-particle-induced DNA damage in peripheral blood mononuclear cells after internal ex vivo irradiation with \(^ | |
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [18F]FDG PET/CT and MRI |